How big is DermTech, Inc.?

As of December 2023, DermTech, Inc. has an unavailable market capitalization. As of March 2024, net sales for the latest four quarters total 15.67 million, with a consolidated net profit of -89.62 million, and shareholder's funds are 57.17 million against total assets of 121.93 million.

Market Cap: As of December 2023, DermTech, Inc. has a market capitalization value that is not available. Therefore, it cannot be classified into any market cap type.<BR><BR>Recent Quarterly Performance: As of March 2024, the sum of net sales for the latest four quarters is 15.67 million. During the same period, the sum of consolidated net profit is -89.62 million.<BR><BR>Balance Sheet Snapshot: As of December 2023, the shareholder's funds amount to 57.17 million, while total assets are reported at 121.93 million.

Should I buy, sell or hold DermTech, Inc.?

Who are in the management team of DermTech, Inc.?

As of March 2022, DermTech, Inc.'s management team includes Independent Chairman Ms. Cynthia Collins, CEO Dr. John Dobak, and several independent directors: Mr. Gary Jacobs, Mr. Scott Pancoast, Mr. Enrico Picozza, Mr. Matthew Posard, and Mr. Herman Rosenman. This team provides governance and strategic direction for the company.

As of March 2022, the management team of DermTech, Inc. includes the following individuals:<BR><BR>- Ms. Cynthia Collins, who serves as the Independent Chairman of the Board.<BR>- Dr. John Dobak, who is the Chief Executive Officer and a Director.<BR>- Mr. Gary Jacobs, an Independent Director.<BR>- Mr. Scott Pancoast, an Independent Director.<BR>- Mr. Enrico Picozza, an Independent Director.<BR>- Mr. Matthew Posard, an Independent Director.<BR>- Mr. Herman Rosenman, an Independent Director.<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.

Is DermTech, Inc. overvalued or undervalued?

As of March 10, 2020, DermTech, Inc. is classified as "risky" and overvalued, with key financial ratios indicating significant distress compared to peers like Cardiff Oncology and Lucid Diagnostics, while Pro-Dex stands out as very attractive.

As of 10 March 2020, DermTech, Inc. has moved from a grade of "does not qualify" to "risky." The company is currently considered overvalued based on its financial metrics. Key ratios include a P/E ratio of 0.00, an EV to EBIT of 0.39, and an EV to EBITDA of 0.42, all indicating significant financial distress and negative capital employed.<BR><BR>In comparison to its peers, DermTech's valuation stands out unfavorably. For instance, Cardiff Oncology, Inc. has a P/E ratio of -5.0384, while Lucid Diagnostics, Inc. also carries a risky designation with a P/E of -2.8046. Notably, Pro-Dex, Inc. is classified as very attractive with a P/E of 15.6736, highlighting the stark contrast in valuations within the sector. Overall, DermTech's financial performance and ratios suggest it is overvalued relative to its peers and the broader market context.

Is DermTech, Inc. technically bullish or bearish?

As of September 3, 2024, DermTech, Inc. exhibits a mildly bearish trend with mixed signals from indicators like MACD and KST showing mild bullishness, while moving averages and Bollinger Bands indicate a lack of clear direction.

As of 3 September 2024, the technical trend for DermTech, Inc. has changed from bearish to mildly bearish. The weekly MACD and KST indicators are both mildly bullish, suggesting some positive momentum, while the daily moving averages indicate a mildly bearish stance. The Bollinger Bands are showing a sideways trend on both weekly and monthly time frames, indicating a lack of clear direction. The Dow Theory and OBV show no trend in either time frame. Overall, the current technical stance is mildly bearish, with mixed signals across different indicators. Multi-period return data is not available for comparison with the S&P 500.